deltatrials
Completed OBSERVATIONAL NCT01872520

Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study

Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza): A Real World Study

Sponsor: Peking University

Updated 8 times since 2017 Last updated: Oct 26, 2015 Started: Jun 30, 2012 Primary completion: Sep 30, 2015 Completion: Sep 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Adverse Drug Reaction, this trial is completed. The trial is conducted by Peking University and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Apr 2018 · 15 months · monthly snapshotCompleted~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed

  2. Sep 2025 — Present [monthly]

    Completed

  3. Sep 2024 — Sep 2025 [monthly]

    Completed

  4. Jul 2024 — Sep 2024 [monthly]

    Completed

  5. Jan 2021 — Jul 2024 [monthly]

    Completed

Show 3 earlier versions
  1. Jun 2018 — Jan 2021 [monthly]

    Completed

  2. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: NANone

  3. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Peking University
  • Peking University Third Hospital
  • Shanghai Greenvalley Pharmaceutical Co., Ltd.
Data source: Peking University Third Hospital

For direct contact, visit the study record on ClinicalTrials.gov .